IP Library Granted Patent US 11,981,923
Granted Patent B2
US 11,981,923 · App. 17/659,624 · Granted May 14, 2024

Pepmixes to generate multiviral CTLS with broad specificity

Inventors: Ann Marie Leen (Houston, TX); Juan Fernando Vera Valdes (Houston, TX); Cliona M. Rooney (Houston, TX); Ulrike Gerdemann (Cambridge, MA)
Assignee: Baylor College of Medicine
C12N5/0638A61K39/12C07K14/025C07K14/03C07K14/11C07K14/135C12N7/00A61K2039/5158A61K2039/55527A61K2039/57A61K2039/572A61K2039/577A61K2039/70C12N2501/2302C12N2501/2304C12N2501/2307C12N2501/2315C12N2710/16134C12N2710/16234Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,981,923
App. No.
17/659,624
Granted
May 14, 2024
Kind
B2
Abstract

The present invention concerns methods of generating CTLs that are able to target at least one antigen from two or more viruses. The method includes exposing mixtures of peptides for different antigens to the same plurality of PBMCs and, at least in certain aspects, expanding the cells in the presence of IL4 and IL7.

Claims (16)

1. A composition comprising an ex vivo expanded polyclonal population of cytotoxic human T lymphocytes (CTLs) that target two or more viral antigens from different viruses;

wherein one or more antigens is from a first virus, and one or more antigens is from a second virus; and wherein

(a) the first virus is BK virus, and the one or more antigens comprise Large T (LT) and viral capsid protein 1 (VP-1); and

(b) the second virus is HHV6 virus, and the one or more antigens comprise U14 and U90.

2. The composition of claim 1 , wherein the CTLs are polyclonal CD4+ and CD8+ CTLs.

3. The composition of claim 1 , wherein the CTLs do not induce detectable evidence of alloreactivity.

4. A method of treating a viral infection or inhibiting viral infection in an individual that has a viral infection or is at risk of a viral infection comprising administering an effective amount of the composition of claim 1 to the individual, wherein the viral infection is a BK viral infection and/or a HHV6 viral infection.

5. The method of claim 4 , wherein the individual is immunocompromised.

6. The method of claim 4 , wherein the individual has had an allogeneic stem cell transplant.

7. A method of killing a virus infected cell in an individual comprising administering an effective amount of the composition of claim 1 to the individual.

8. A composition comprising an ex vivo expanded population of cytotoxic human T cells (CTLs) that target two or more viral antigens from different viruses, wherein the CTLs are reactive to one or more libraries of peptides, said one or more libraries of peptides each comprising peptides that overlap in sequence or span part or all of said two or more viral antigens, wherein each peptide is at least seven amino acids in length, wherein one or more antigens is from a first virus and one or more antigens is from a second virus; and wherein

(a) the first virus is BK virus, and the one or more antigens are selected from LT and VP-1; and

(b) the second virus is HHV6 virus, and the one or more antigens are selected from U14, U11, U71, U54, and U90.

9. The composition of claim 8 , wherein the peptides are each 15 amino acids in length and overlap by 11 amino acids.

10. The composition of claim 8 , wherein the peptides span the entire length of each of the multiple antigens.

11. The composition of claim 8 , wherein the CTLs do not induce detectable evidence of alloreactivity.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2022
From: LEEN, ANN MARIE; VERA VALDES, JUAN FERNANDO; ROONEY, CLIONA M.; GERDEMANN, ULRIKE
To: BAYLOR COLLEGE OF MEDICINE
Reel/Frame 059633/0920 →
Continuity (5)
Continuation 17443261 · Jul 23, 2021
Continuation 15905176 · Feb 26, 2018
Continuation 14377825
Provisional Application 61596875 · Feb 9, 2012
Related Publication 20220251508A1 · Aug 11, 2022